- Home
- ADIG vs TSHA Comparison
ADIG vs TSHA Comparison
Compare ADIG & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ADIG | TSHA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2026 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ADIG | TSHA |
|---|---|---|
| Price | $27.68 | $6.63 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $11.63 |
| AVG Volume (30 Days) | 1.6M | ★ 2.8M |
| Earning Date | N/A | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.56 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $9,773,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,152.42 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.28 |
| 52 Week Low | $26.75 | $2.72 |
| 52 Week High | $28.91 | $7.30 |
Technical Indicators
Market Signals| Indicator | ADIG | TSHA |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 61.32 |
| Support Level | N/A | $5.28 |
| Resistance Level | N/A | $7.06 |
| Average True Range (ATR) | 0.00 | 0.37 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 0.00 | 98.59 |
Price Performance
Historical ComparisonAbout TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a clinical-stage biotechnology company focused on advancing AAV-based gene therapies for the treatment of severe monogenic diseases of the central nervous system, or CNS. The company's clinical program TSHA-102 is in development for the treatment of Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies that address the genetic root cause of the disease. The Company views its operations and manages its business as a single operating segment, the gene therapy segment, which is the business of developing AAV-based gene therapies for the treatment of rare monogenic diseases of the central nervous system.